AI IN POLYCYSTIC OVARY SYNDROME: REVOLUTIONIZING DIAGNOSIS AND MANAGEMENT

Divya R. Patil [1], Nitin R. kale [2], Dr. Gajanan Sanap[3] , Shivshankar M. Nagrik [4]

Student, B. Pharm Final Year , Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Chha. Sambhaji Nagar, India .1

Asst. Prof, Department of Pharmacology, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Chha. Sambhaji Nagar, India.2

Principal, Department of Pharmacology, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Chha. Sambhaji Nagar, India.3

ABSTRACT

Polycystic Ovary Syndrome (PCOS) is an endocrine disorder common among 4–20% of women in reproductive age. Reproductive, metabolic, and psychological implications of the syndrome are high. Present approaches for diagnosing PCOS have several issues associated with subjectivity, variability, and delayed diagnosis through clinical examination, biochemical investigations, and imaging. The rise of AI technology has made it a game changer in dealing with the problems related to diagnosis and provides enhanced diagnostic precision and speed through ML and DL models. This paper reviews the contribution of AI technologies in PCOS prediction and diagnosis. AI models, supervised as well as unsupervised, perform better than conventional approaches with large, complex data sets. Random forests and ANNs have reached high diagnostic accuracies over 90%, and patients are clustered into phenotypes for treatment tailored by unsupervised clustering techniques. They embrace clinical, genetic and imaging data with non-invasive diagnosis, early diagnoses and cost effective interventions. SHAP and LIME are two other forms of AI structures of explanatory methods for added model explainability and increased clinician trust. When it comes to prediction of risk of developing PCOS by using AI the genetic factors, lifestyle parameters, and a family history of PCOS is used accurately up to 96 percent. Innovations in diagnostics include analysis of ultrasound images coupled with identification of biomarkers using AI including hormonal concentrations and ovarian follicles, which combine to boost reliability, particularly within clinical or resource scarce environments. Some concerns are yet to be faced; these are the scarcity of unified and varied databases, problem of heterogeneity of diagnosis procedures, data protection issues, and prejudicial AI systems. Challenges of these limitations include; Future directions entail creating models that can be explained, combining various data input for comprehensive diagnosis, and controlling big, detailed databases. In a syncronized form, AI from wearable to portable health applications will be foreshadow to follow patients by engaging them in real time for better treatment. To offer solutions for healthcare that originate from artificial intelligence and that are honest and fair, ethical and regulatory issues have to be resolved. The strength of this review is to use AI to predict the diagnosis and treatment of PCOS for personalized, efficient, and accessible medical care, and several directions for improvement.

Key Words: *Polycystic Ovary Syndrome, Diagnostic Criteria, Artificial Intelligence, Data Privacy, Global Applicability*

1- INTRODUCTION

Polycystic Ovary Syndrome is an endocrine disorder that can be found in over 80% of women of childbearing age. It is characterized by hyperandrogenism, ovulation disturbances and polycystic ovarian morphology. Figures suggest that 4-20 % of women globally have PCOS depending on the adopted criteria. This disorder has serious impacts on reproduction, metabolism and psychology of the patient, hence infertility, insulin resistance, type 2 diabetes, and depression [1].

Salah and Fankhauser 289 established that diagnosing PCOS is not easy because of the diversity in the clinical manifestations and the diagnostic requirements of the NIH, Rotterdam, and the Androgen Excess-PCOS Society protocols. All these disparities result into early or under diagnosis, therefore increased cases of unattended complications. Historically, the diagnosis depends on the clinical examination, biochemical assay, and imaging studies, all of which have been known to be time consuming, subjective and have inherent inter and intra observer variation [2].

Healthcare is arguably one of largest beneficiaries of AI that we have in the contemporary world today thanks to the ML and DL. Approach is improved, human produced errors are eliminated and the technologies can effectively manage large volumes of data. In PCOS management, the AI improves early diagnosis, differentiation, and recommendation of management strategies [3]. For instance, Random Forest algorithms and artificial neural networks have yielded high diagnostic accuracy that was as high as 96% [4].



Figure No.1. Difference between the normal and polycystic overay

2. AI TECHNOLOGIES IN HEALTHCARE

AI is the science by which systems are developed to mimic, learn, reason, and solve problems like human beings. Machine Learning (ML) is a branch of AI, which aims to compute reliable predictive models from big data. The technologies are finding application in the diagnosis and management of diseases in healthcare including the Polycystic Ovary Syndrome (PCOS).

2.1. Varieties of AI Models Applied in Healthcare

Supervised Learning Models: These models are employed on labeled datasets in order to forecast outcomes. For instance, decision tree and random forests are extensively used for PCOS prediction, which are effective to obtain high accurate prediction since the model could analyse the large amount of highly non-linear features of complex high-dimensional data [5]. Further, while using logistic regression and support vector machines there is successful outcome with good accuracy, many a times is more than 85%[6]. Unsupervised Learning Models. These models automatically discover hidden patterns in data that do not require labeled results. Clustering algorithms, for example, k-means, are used to cluster patients into specified subcategories such as BMI and hormonal levels so that patients could be treated specifically [7].

Deep Learning Methods: ANNs, in particular, predominate in the diagnosis of PCOS. Through detailed analysis of large data sets of clinical and imaging and genetic data, they achieve an accuracy rate of over 90 percent [8].

2.2. Comparing AI with other conventional diagnostic methods

Increased Accuracy: Random forests and neural networks yield better results than conventional approaches so they come with a higher levels of accuracy and can also possess a lower level of humans errors[9].

Early Detection: AI can detect PCOS in the at-risk populations much earlier through subtle clinical and genetic markers for timely intervention [10].

Non-Invasive Diagnosis: AI models use non-invasive features, such as lifestyle data and ultrasound imaging, thus making diagnostics patient-friendly and accessible [11].

Cost Efficiency: Implementation of AI in diagnostics eliminates the need to employ specialized personnel and equipment hence lowering the costs of diagnoses without leading to compromising the quality [12].

3. ADAPTING AI IN PREDICTING AND DIAGNOSING OF PCOS

3.1 PCOS Risk Prediction

In a study, AI was clearly shown to have high capabilities when it comes to determining the possibility of Polycystic Ovary Syndrome (PCOS) based on different factors such as genes, habits, and ancestry.

AI-based Frameworks for PCOS Risk Assessment:

Genetic Predisposition: AI models, especially those that rely on the application of neural networks and genetic algorithms, utilized genetic markers in identifying women that are predisposed to PCOS. This will explain the heritability of PCOS while early detection is performed [13].

Lifestyle and Environmental Factors: The lifestyle factors are obesity, diet, and patterns of physical activity, now included in the AI models. Inclusion of non-invasive measurements like body mass index and dietary habits into the prediction model showed accuracy for predicting the risk of PCOS up to 81-90% [14].

Family History and Epigenetics: Family history integrated with genomic datasets like MethylChip data increases the risk assessment of the cancer. These tools over-emphasize the complexity of PCOS and help in risk profiling[15].

Case Studies and Examples of Predictive AI Algorithms:

Machine Learning Algorithms: Machine learning methods such as random forests and boosting have been employed in studies on prediction of PCOS based on clinic/radiological features, with a diagnostic accuracy not less than 96% [16]. ANNs: They have assisted in forecasting of PCOS with factors such as hormonal and lifestyles and has been used in construction of dynamic and precise models for diagnostic [17].

Explainable AI Tools: SHAP and LIME methods offered transparency for prediction, which improved the trust in these models [18].

3.2 Diagnosing PCOS

AI in Extraction of Diagnostic Criteria: In diagnosis of PCOS, hyperandrogenism, irregular menstrual cycle, and morphology of the ovary have been successfully diagnosed using artificial intelligence (AI). In clinical, biochemical, and image analysis diagnosis AI has been proven to be accurate than other methods due to its ability to combine the clinical, biochemical, and imaging analyses [19].

Restoration of Ultrasound Images & Computer-Aided Diagnosis: In evaluating ultrasound images,

the AI-based systems have been integrated. Despite this, such systems have greatly reduced the chances of human error and the time taken to diagnose ovarian abnormalities. By using methods like segmenting, classifying, and the incorporating of deep learning algorithm the accuracy is raised [20].

AI-Based Biomarkers for Early Detection: Potential identification of biomarkers by using AI-driven machine learning models on hormone levels and ovarian follicle counts that might lead to an early diagnosis of PCOS; this diagnostic tool is enhancing reliability, mainly when applied on a large scale of outpatient population sizes [21].

4. KEY AI TOOLS AND PLATFORMS FOR PCOS

Polycystic Ovary Syndrome has been greatly diagnosed and treated through the help of the new discovery of artificial intelligence (AI). In this section, the AI-based diagnostic instruments and platforms that exist today are described together with the algorithm used in each of the studies from various sources, with some specific tools or models that can both applied clinically and for research purposes.

4.1 Overview of Existing AI-Based Diagnostic Tools and Platforms

AI-based diagnostic platforms for PCOS integrate clinical, imaging, and genomic data to enhance the accuracy and speed of diagnosis. A number of studies have been performed that showed the possibility of AI use in non-invasive diagnostic platforms. For instance:

Machine Learning-Based Self-Diagnostic Tools: These diagnostic platforms depend on non-invasive measurements, such as lifestyle factors and anthropometric data, to predict PCOS with 81-90% accuracy [22].

EHR-Integrated Predictive Models: Machine learning algorithms applied to electronic health records (EHR) enable the identification of at-risk individuals, with predictive accuracies up to 85% [23].

4.2 Comparison of the Algorithms used in AI for PCOS Research

AI algorithms differ in their approaches and performance when diagnosing PCOS:

Random Forest and Gradient Boosting Algorithms: As these models demonstrate various aspects of high diagnostic accuracy. For instance, Random Forest attained 96% accuracy in PCOS detection [24].

Support Vector Machines (SVM): Used more often, sensitivity and specificity of SVM algorithms varied between 75% and 100% [25].

Artificial Neural Networks (ANN): ANN techniques are centred on feature extraction and give reliable predictions of the extent of PCOS, with predicted accuracies as high as 97.8 per cent [26].

4.3 Specific tools/models working in clinical and numerical research environments only

Clinical tools and research models integrating AI for PCOS diagnosis are pivotal:

Explainable AI Frameworks: For example, Explainable Machine Learning (XAI) tools like SHAP and LIME help clinicians obtain models related to their decision-making processes [27].

Transvaginal Ultrasound Automation: Quantification of follicle count and morphology from ultrasound imaging using AI platform decreases human interference and improves diagnostic effectiveness [28].

5. BENEFITS OF AI IN PCOS MANAGEMENT

Benefit	Description	Key Study/Insight
Improved Diagnostic Accuracy and Reduced Human Error	AI-driven tools analyze large datasets with complex algorithms, identifying subtle patterns and reducing misdiagnoses and variability.	ML models for ultrasound image analysis achieved diagnostic accuracies exceeding 90% [29].
Enhanced Ability to Detect PCOS in Early Stages	AI enables early detection by integrating diverse parameters (hormonal levels, metabolic profiles, etc.) to flag risks before clinical escalation.	A predictive AI framework showed superior sensitivity for early-stage PCOS detection compared to traditional criteria [30].
Personalization of Diagnosis and Management Plans Based on AI-Driven Insights	AI facilitates personalized management by stratifying patients into phenotypes based on genetic, metabolic, and clinical profiles, ensuring targeted treatment.	AI models improved glycemic control and symptom resolution with tailored treatment plans incorporating genetic and lifestyle factors [31].
Time and Cost-Effectiveness of AI Tools in Resource-Constrained Settings	AI tools address healthcare barriers in low-resource areas by reducing reliance on specialists and costly diagnostics, ensuring equitable healthcare.	AI-powered mobile applications effectively diagnosed PCOS with minimal equipment, reducing costs and consultation times [32].

Table no.1. Benefits of AI in PCOS management

6. CHALLENGES AND LIMITATIONS

Current advanced technologies such as artificial intelligence are now widely practiced in the field of forecasting and diagnosis of polycystic ovary syndrome compared to traditional methods. Nevertheless, it is a relatively young area of science, and there are numerous remaining issues and constraints in the multifield area.There is a scarcity of extensive, standardized datasets for training AI.

AI systems feed on high-quality and diversified datasets to attain predictive accuracy. The lack of standardized and extensive datasets for PCOS severely restricts the generalizability and applicability of AI models. Most datasets currently available are small, region-specific, and heterogeneous, thereby restricting their ability to accurately predict PCOS across diverse populations. For example, researchers have commented that deficiencies in datasets hamper the reproducibility and reliability of AI outcomes [33].

Inconsistency of PCOS Diagnostic Criteria Between Populations: Another challenge that AI applications face is inconsistency in PCOS diagnostic criteria, such as Rotterdam, NIH, and Androgen Excess Society criteria. The number of differences creates conflicting predictions by AI, further complicated by clinical practices around the world. Such inconsistencies undermine the consistent development of reliable AI tools and contribute further to diagnostic ambiguity [34].

Ethical Considerations in Relation to Data Privacy and Security: Healthcare systems driven by artificial intelligence are significantly based on private patient data, raising ethical issues of privacy and data protection. Balancing compliance with strict data governance requirements, such as GDPR, with accessibility for model training is a very challenging task. Violations of confidentiality may prevent patients from providing crucial information, thereby compromising the quality of datasets [35].

Potential for Bias in AI Algorithms as a Result of Unbalanced Datasets: Datasets that are overrepresented by some populations create significant biases in the AI models themselves. For instance, an algorithm trained on an overrepresentation of certain ethnicities or socioeconomic populations may have low accuracy for their underrepresented peers. These may lead to pernicious persistence of healthcare inequalities and potentially also undermine trust within diverse populations about AI systems [36].

Complexities in Deploying AI Technologies in Clinical Contexts: Deploy AI solutions as a complement to the current clinical processes, that is, a fundamental shift of paradigm and structure. A major concern clinicians are going to experience will be the inability to understand why AI has arrived at a certain prediction given the black box nature of most AI models. Also, lack of procedures on how to integrate AI can hinder early and seamless deployment of value of AI in diagnosing PCOS [37].

7.FUTURE DIRECTIONS IN AI FOR PCOS DIAGNOSIS

Developing More Robust and Interpretable AI Models: AI's "black box" remains a major barrier to its universal adoption in the clinical field. Developing models interpretable and providing explainable results is necessary to enhance the clinicians' confidence as well as understanding of the patient's condition. A robust model which can account for the variability of phenotypic expressions of PCOS would help ensure the robustness across the populations [37].

Multimodal Data Integration for Comprehensive PCOS Diagnosis: The strength of AI is obtained when it is processing big and complex data sets. The model in the future should include other data modalities like genomics proteomics metabolomics and imaging data. This kind of extensive examination will let the researchers find more biomarkers and gain the full picture of the pathophysiology of PCOS. For example, ultrasound imaging data integrated with hormonal profiling and genetic data will result in higher sensitivity and specificity with better treatment decisions for individuals [38].

Development of Large Diverse Datasets through Collaborations: Among the greater challenges in the AI applications that have to be met with in PCOS is that validation and development rely on the availability of large, representative datasets. To this purpose, it is paramount to develop diverse datasets, with involvement by researchers, healthcare institutions, and developers in technology. This type of datasets will only increase the generalizability of AI algorithms, and ultimately, will make them applicable to global populations [39].

Inclusion of AI Tools in Wearable Devices and Mobile Health Applications: AI is complemented by wearable devices and mobile applications for subsequently observing the patient’s quantitative and qualitative parameters physical activity, sleep deficit/overshot, hormonal imbalance. These platforms together with AI algorithms is possible for the constant monitoring of PCOS symptoms as a way of early diagnosis. In addition, it can also be applied to engage patient within the treatment plan and self-monitoring [40].

Methods to Overcome Ethical and Regulatory Challenges: The integration of AI in the diagnosis of PCOS raises ethical and regulatory issues such as data privacy, security, and bias within algorithms. All these need standardized guidelines on how AI should be applied in health care, open algorithm development to transparency, and ensure that regulation frameworks address equality in AI health care delivery [41].

8-CONCLUSION

The integration of artificial intelligence in the diagnostic and therapeutic procedures for Polycystic Ovary Syndrome is one of the significant breakthroughs in the healthcare sector. AI techniques, including machine learning and deep learning, have an accuracy, effectiveness, and personalization that no traditional diagnostic techniques could ever provide. The multimodal data applied here, such as clinical, genetic, and imaging information, make early detection and classification of PCOS possible and eventually lead to personalized treatment plans. Such methods as Random Forest algorithms, artificial neural networks, and explainable AI frameworks have shown substantial diagnostic accuracy up to 96%. Despite the promises, there are several challenges in applying AI to PCOS; for example, lack of standardized, diverse datasets, varied diagnostic criteria, and the ethical aspects in data privacy and algorithmic bias. These necessitate comprehensive joint endeavors in creating resilient and comprehensible models, alongside regulatory structures that guarantee equal health care provision. Future directions encompass the incorporation of wearable technologies and mobile health applications to facilitate real-time monitoring and early symptom detection, hence enhancing patient participation. The integration of diverse data kinds and the advancement of explainable artificial intelligence systems will augment their acceptance and dependability in therapeutic environments. Artificial intelligence, via ongoing research and collaboration, has the potential to transform the diagnosis and treatment of polycystic ovarian syndrome, enhancing the health of millions of women globally.

REFERENCES

1. Barrera FJ, Brown ED, Rojo A, Obeso J, Plata H, Lincango EP, Terry N, Rodríguez-Gutiérrez R, Hall JE, Shekhar S. Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: a systematic review. Frontiers in Endocrinology. 2023 Sep 18;14:1106625.
2. Zad Z, Jiang VS, Wolf AT, Wang T, Cheng JJ, Paschalidis IC, Mahalingaiah S. Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. Frontiers in Endocrinology. 2024 Jan 30;15:1298628.
3. Bharati S, Podder P, Mondal MR. Diagnosis of polycystic ovary syndrome using machine learning algorithms. In2020 IEEE region 10 symposium (TENSYMP) 2020 Jun 5 (pp. 1486-1489). IEEE.
4. Vishwakarma V, Chethan S, Datla MT, Aqib MM, Roy S, Thasni T. Prediction of severity of polycystic ovarian syndrome using artificial neural networks. InSecond International Conference on Image Processing and Capsule Networks: ICIPCN 2021 2 2022 (pp. 589-598). Springer International Publishing.
5. Bharati S, Podder P, Mondal MR. Diagnosis of polycystic ovary syndrome using machine learning algorithms. In2020 IEEE region 10 symposium (TENSYMP) 2020 Jun 5 (pp. 1486-1489). IEEE.

6. Zad Z, Jiang VS, Wolf AT, Wang T, Cheng JJ, Paschalidis IC, Mahalingaiah S. Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. Frontiers in Endocrinology. 2024 Jan 30;15:1298628.
7. Zigarelli A, Jia Z, Lee H. Machine-aided self-diagnostic prediction models for polycystic ovary syndrome: observational study. JMIR Formative Research. 2022 Mar 15;6(3):e29967.
8. Vishwakarma V, Chethan S, Datla MT, Aqib MM, Roy S, Thasni T. Prediction of severity of polycystic ovarian syndrome using artificial neural networks. InSecond International Conference on Image Processing and Capsule Networks: ICIPCN 2021 2 2022 (pp. 589-598). Springer International Publishing.
9. Deepika V. Applications of artificial intelligence techniques in polycystic ovarian syndrome diagnosis. J. Adv. Res. Technol. Manag. Sci. 2019 Nov;1(3):59-63.
10. Barrera FJ, Brown ED, Rojo A, Obeso J, Plata H, Lincango EP, Terry N, Rodríguez-Gutiérrez R, Hall JE, Shekhar S. Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: a systematic review. Frontiers in Endocrinology. 2023 Sep 18;14:1106625.
11. Agrawal A, Ambad R, Lahoti R, Muley P, Pande PS. Role of artificial intelligence in PCOS detection. Journal of Datta Meghe Institute of Medical Sciences University. 2022 Apr 1;17(2):491-4.
12. Zad Z, Jiang VS, Wolf AT, Wang T, Cheng JJ, Paschalidis IC, Mahalingaiah S. Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. Frontiers in Endocrinology. 2024 Jan 30;15:1298628.
13. Zad Z, Jiang VS, Wolf AT, Wang T, Cheng JJ, Paschalidis IC, Mahalingaiah S. Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. Frontiers in Endocrinology. 2024 Jan 30;15:1298628.
14. Zigarelli A, Jia Z, Lee H. Machine-aided self-diagnostic prediction models for polycystic ovary syndrome: observational study. JMIR Formative Research. 2022 Mar 15;6(3):e29967.
15. Chitra P, Sumathi M, Srilatha K, Jayasudha FV, Amudha S. Review of Artificial Intelligent based Algorithm for Prediction of Polycystic Ovary Syndrome (PCOS) from Blood Samples. In2022 4th International Conference on Inventive Research in Computing Applications (ICIRCA) 2022 Sep 21 (pp. 1172-1176). IEEE.
16. Bharati S, Podder P, Mondal MR. Diagnosis of polycystic ovary syndrome using machine learning algorithms. In2020 IEEE region 10 symposium (TENSYMP) 2020 Jun 5 (pp. 1486-1489). IEEE.
17. Vishwakarma V, Chethan S, Datla MT, Aqib MM, Roy S, Thasni T. Prediction of severity of polycystic ovarian syndrome using artificial neural networks. InSecond International Conference on Image Processing and Capsule Networks: ICIPCN 2021 2 2022 (pp. 589-598). Springer International Publishing.
18. Khanna VV, Chadaga K, Sampathila N, Prabhu S, Bhandage V, Hegde GK. A distinctive explainable machine learning framework for detection of polycystic ovary syndrome. Applied System Innovation. 2023 Feb 23;6(2):32.
19. Barrera FJ, Brown ED, Rojo A, Obeso J, Plata H, Lincango EP, Terry N, Rodríguez-Gutiérrez R, Hall JE, Shekhar S. Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic

ovarian syndrome: a systematic review. Frontiers in Endocrinology. 2023 Sep 18;14:1106625.

20. Makhdoomi A, Jan N, Palak P, Goel N. Machine learning techniques for medical images in PCOS. In2022 4th International Conference on Artificial Intelligence and Speech Technology (AIST) 2022 Dec 9 (pp. 1-6). IEEE.
21. Zad, Z., Jiang, V., Wolf, A., Wang, T., Cheng, J., Paschalidis, I., & Mahalingaiah, S., 2024. Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. *Frontiers in Endocrinology*, 15. https://doi.org/10.3389/fendo.2024.1298628.
22. Zigarelli A, Jia Z, Lee H. Machine-aided self-diagnostic prediction models for polycystic ovary syndrome: observational study. JMIR Formative Research. 2022 Mar 15;6(3):e29967.
23. Zad Z, Jiang VS, Wolf AT, Wang T, Cheng JJ, Paschalidis IC, Mahalingaiah S. Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. Frontiers in Endocrinology. 2024 Jan 30;15:1298628.
24. A, A., S, S., N, V., R, V., & N, V., 2022. Diagnosis of Polycystic Ovary Syndrome using Machine Learning Algorithms. *International Journal of Advanced Research in Science, Communication and Technology*. https://doi.org/10.48175/ijarsct-5174.
25. Bharati S, Podder P, Mondal MR. Diagnosis of polycystic ovary syndrome using machine learning algorithms. In2020 IEEE region 10 symposium (TENSYMP) 2020 Jun 5 (pp. 1486-1489). IEEE.
26. Barrera FJ, Brown ED, Rojo A, Obeso J, Plata H, Lincango EP, Terry N, Rodríguez-Gutiérrez R, Hall JE, Shekhar S. Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: a systematic review. Frontiers in Endocrinology. 2023 Sep 18;14:1106625.
27. Khanna VV, Chadaga K, Sampathila N, Prabhu S, Bhandage V, Hegde GK. A distinctive explainable machine learning framework for detection of polycystic ovary syndrome. Applied System Innovation. 2023 Feb 23;6(2):32.
28. Agrawal A, Ambad R, Lahoti R, Muley P, Pande PS. Role of artificial intelligence in PCOS detection. Journal of Datta Meghe Institute of Medical Sciences University. 2022 Apr 1;17(2):491-4.
29. Liu B, Xia H, Zhang J, Hu Y, Wang Q. Building Personalized Risk Prediction Models for Polycystic Ovary Syndrome Using Machine Learning Techniques: A Retrospective Study. Available at SSRN 4865261.
30. Stafie CS, Sufaru IG, Ghiciuc CM, Stafie II, Sufaru EC, Solomon SM, Hancianu M. Exploring the intersection of artificial intelligence and clinical healthcare: a multidisciplinary review. Diagnostics. 2023 Jun 7;13(12):1995.
31. Huang T, Xu H, Wang H, Huang H, Xu Y, Li B, Hong S, Feng G, Liu G, Jiang D, Li ZC. Artificial intelligence for medicine: Progress, challenges, and perspectives. The Innovation Medicine. 2023;1(2).
32. GhoshRoy D, Alvi PA, Santosh KC. AI tools for assessing human fertility using risk factors: A state-of-the-art review. Journal of Medical Systems. 2023 Aug 23;47(1):91.
33. Novakovic S, Jakovljevic V, Jovic N, Andric K, Milinkovic M, Anicic T, Pindovic B, Kareva EN, Fisenko VP, Dimitrijevic A, Joksimovic Jovic J. Exploring the Antioxidative Effects of Ginger and Cinnamon: A Comprehensive Review of Evidence and Molecular

Mechanisms Involved in Polycystic Ovary Syndrome (PCOS) and Other Oxidative Stress-Related Disorders. Antioxidants. 2024 Mar 25;13(4):392.

34. Kiconco S, Teede HJ, Azziz R, Norman RJ, Joham AE. The need to reassess the diagnosis of polycystic ovary syndrome (PCOS): a review of diagnostic recommendations from the international evidence-based guideline for the assessment and management of PCOS. InSeminars in reproductive medicine 2021 Jul (Vol. 39, No. 03/04, pp. 071-077). Thieme Medical Publishers, Inc..
35. Obermeyer Z, Emanuel EJ. Predicting the future—big data, machine learning, and clinical medicine. New England Journal of Medicine. 2016 Sep 29;375(13):1216-9.
36. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine. 2019 Jan;25(1):44-56.
37. Verma P, Maan P, Gautam R, Arora T. Unveiling the role of artificial intelligence (AI) in polycystic ovary syndrome (PCOS) diagnosis: A comprehensive review. Reproductive Sciences. 2024 Oct;31(10):2901-15.
38. Barrera FJ, Brown ED, Rojo A, Obeso J, Plata H, Lincango EP, Terry N, Rodríguez-Gutiérrez R, Hall JE, Shekhar S. Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: a systematic review. Frontiers in Endocrinology. 2023 Sep 18;14:1106625.
39. Singh S, Maurya MK, Singh NP, Kumar R. Survey of AI-driven techniques for ovarian cancer detection: state-of-the-art methods and open challenges. Network Modeling Analysis in Health Informatics and Bioinformatics. 2024 Oct 7;13(1):56.
40. Kumar NU. Unveiling the Complexity of PCOD: Exploring Contemporary Research and Scientific Breakthroughs Review. Asian Journal of Pharmaceutics (AJP). 2023 Dec 15;17(04).
41. Graca S, Alloh F, Lagojda L, Dallaway A, Kyrou I, Randeva HS, Kite C. Polycystic ovary syndrome and the internet of things: a scoping review. InHealthcare 2024 Aug 21 (Vol. 12, No. 16, p. 1671). MDPI.